# Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor

Study · id `cardio:ct-nct02627521` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02627521](<https://clinicaltrials.gov/study/NCT02627521>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02627521

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 260 participants.

## Technical summary

Registry record NCT02627521. Randomized; triple masking; primary purpose treatment. Start 2015-07 (registry gives no type); primary completion 2017-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 260 participants (planned count; ClinicalTrials.gov record NCT02627521, source copy `cardio:ctgov-nct02627521-2017-02-16`, retrieved 2026-10-26)
- Start date: 2015-07 (registry gives no type) (ClinicalTrials.gov record NCT02627521, source copy `cardio:ctgov-nct02627521-2017-02-16`, retrieved 2026-10-26)
- Primary completion: 2017-08 (anticipated) (ClinicalTrials.gov record NCT02627521, source copy `cardio:ctgov-nct02627521-2017-02-16`, retrieved 2026-10-26)
- Completion: 2017-08 (anticipated) (ClinicalTrials.gov record NCT02627521, source copy `cardio:ctgov-nct02627521-2017-02-16`, retrieved 2026-10-26)
- Countries: Canada (ClinicalTrials.gov record NCT02627521, source copy `cardio:ctgov-nct02627521-2017-02-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02627521-2017-02-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor
- Acronym: CABG-TIME
- Condition: Coronary Artery Disease
- Intervention (Procedure): PRU guided CABG
- Intervention (Procedure): CABG per standard of care
- Intervention (Device): VerifyNow assay
- Intervention (Drug): Ticagrelor
- Lead sponsor: Unity Health Toronto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Ticagrelor (`cardio:ticagrelor`)
- Registry lists this organization as the lead sponsor: Unity Health Toronto (`cardio:org-unity-health-toronto`)

## Provenance

Content hash: 7fe634aaee9f1c5193021861753e439da4aa475010e54d87a979d37701045e5e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
